You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Gaboxadol

Showing 1 - 17 of 17
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Fragile X Syndrome Trial in Australia, United States (Sulindac (HLX-0201), dose strength 1, Sulindac (HLX-0201), dose strength

Withdrawn
  • Fragile X Syndrome
  • Sulindac (HLX-0201), dose strength 1
  • +3 more
  • Aurora, Colorado
  • +9 more
Dec 7, 2022

Angelman Syndrome Trial in Israel, United States (OV101 Regimen 1, OV101 regimen 2, Placebo)

Completed
Has Results
  • Angelman Syndrome
  • OV101 Regimen 1
  • +2 more
  • Phoenix, Arizona
  • +12 more
Mar 3, 2022

Angelman Syndrome Trial in Israel, United States (OV101)

Terminated
  • Angelman Syndrome
  • Phoenix, Arizona
  • +10 more
Jan 20, 2022

Primary Disease or Condition Being Studied: Angelman Syndrome (AS) Trial in Worldwide (Gaboxadol, Placebo)

Completed
  • Primary Disease or Condition Being Studied: Angelman Syndrome (AS)
  • Gaboxadol
  • Placebo
  • Phoenix, Arizona
  • +13 more
Nov 16, 2020

Fragile X Syndrome (FXS) Trial in United States (OV101 (gaboxadol))

Completed
  • Fragile X Syndrome (FXS)
  • OV101 (gaboxadol)
  • Sacramento, California
  • +5 more
May 8, 2020

Angelman Syndrome, Fragile X Syndrome Trial in Chicago, Nashville (OV101)

Completed
  • Angelman Syndrome
  • Fragile X Syndrome
  • Chicago, Illinois
  • +1 more
Nov 29, 2017

Primary Insomnia Trial (MK0928, gaboxadol / Duration of Treatment 3 Weeks, Placebo / Duration of Treatment 3 Weeks)

Completed
  • Primary Insomnia
  • MK0928, gaboxadol / Duration of Treatment 3 Weeks
  • Placebo / Duration of Treatment 3 Weeks
  • (no location specified)
Jan 13, 2015

Insomnia Trial (gaboxadol)

Completed
  • Insomnia
  • gaboxadol
  • (no location specified)
Jan 13, 2015

Primary Insomnia Trial (MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose), Placebo /

Terminated
  • Primary Insomnia
  • MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)
  • Placebo / Duration of Treatment: 2 days for screening period
  • (no location specified)
Jan 13, 2015

Insomnia Trial (gaboxadol, Comparator: (unspecified))

Completed
  • Insomnia
  • gaboxadol
  • Comparator: placebo (unspecified)
  • (no location specified)
Jan 13, 2015

Insomnia Trial (MK0928, gaboxadol / Duration of Treatment: 10 months)

Withdrawn
  • Insomnia
  • MK0928, gaboxadol / Duration of Treatment: 10 months
  • (no location specified)
Jan 13, 2015

MDD Trial in Austria, Russian Federation (Escitalopram , Gaboxadol , Escitalopram 20 mg)

Completed
Has Results
  • Major Depressive Disorder
  • Escitalopram placebo
  • +4 more
  • Vienna, Austria
  • +21 more
Dec 13, 2012

Primary Insomnia Trial (Gaboxadol)

Completed
  • Primary Insomnia
  • Gaboxadol
  • (no location specified)
Mar 29, 2007

Primary Insomnia Trial (Gaboxadol)

Completed
  • Primary Insomnia
  • Gaboxadol
  • (no location specified)
Mar 29, 2007

Primary Insomnia Trial in Göteborg (Gaboxadol)

Completed
  • Primary Insomnia
  • Gaboxadol
  • Göteborg, Sweden
    Non-US study, principal location:
Mar 29, 2007

Primary Insomnia Trial in Göteborg (Gaboxadol)

Completed
  • Primary Insomnia
  • Gaboxadol
  • Göteborg, Sweden
    Non-US study, principal location:
Mar 29, 2007

Primary Insomnia Trial in Regensburg (Gaboxadol)

Completed
  • Primary Insomnia
  • Gaboxadol
  • Regensburg, Germany
    Non-US study, principal location:
Mar 29, 2007